Chapter 1: The Management of Erectile Dysfunction: An Aua Update

Montague, Drogo K.; Jarow, Jonathan P.; Broderick, Gregory A.; Dmochowski, Roger R.; Heaton, Jeremy P.W.; Lue, Tom F.; Milbank, Aaron J.; Nehra, Ajay; Sharlip, Ira D.

doi:10.1097/01.ju.0000164463.19239.19

Cited by 298 publications

(208 citation statements)

References 47 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…9 It is currently a second-line therapy along with intracavernosal self-injection and intraurethral therapy with vasoactive substances. 20 It is widely believed that VCD therapy is more acceptable among elderly patients with occasional sexual intimacy, as younger patients may show limited acceptance because of its perceived 'unnatural' erection. 21 Chen et al, conversely, reported that VCD therapy remained the preferred treatment option among couples who had achieved satisfactory erections with either VCDs and PDE 5 I.…”

Section: Historymentioning

confidence: 99%

Vacuum therapy in erectile dysfunction—science and clinical evidence

et al. 2010

View full text Add to dashboard Cite

Vacuum therapy (VT) utilizes negative pressure to distend the corporal sinusoids and to increase the blood inflow to the penis. Depending on its purpose, VT could be used as vacuum constriction device (VCD), with the aid of an external constricting ring which is placed at the base of penis to prevent blood outflow, maintaining the erection for sexual intercourse. Also, as a vacuum erectile device (VED), without the application of a constriction ring, just increases blood oxygenation to the corpora cavernosa and for other purposes. The emerging of phosphodiesterase 5 inhibitors (PDE 5 I) for the treatment of erectile dysfunction (ED) eclipsed VCD as therapeutic choice for ED; however, widespread usage of VED as part of penile rehabilitation after radical prostatectomy and other purposes rekindle the interest for VT. The underlying hypothesis is that the artificial induction of erections shortly after surgery facilitates tissue oxygenation, reducing cavernosal fibrosis in the absence of nocturnal erections, and potentially increases the likelihood of preserving erectile function. Due to its ability to draw blood into the penis regardless of nerve disturbance, VED has become the centerpiece of penile rehabilitation protocols. Herein, we reviewed the history, mechanism, application, side effects and future direction of VT in ED.

show abstract

Section: Historymentioning

confidence: 99%

Vacuum therapy in erectile dysfunction—science and clinical evidence

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The American Urological Association's Update on the Management of Erectile Dysfunction in 2005 recommended that 'future research in penile prosthesis implantation should always express survival using Kaplan-Meier methods and include data on the numbers of patients censored.' 58 Eight such studies were found (Table 4). Since the publication of the report, we have published a report of 455 men implanted with the AMS 700 CX or CXM penile prosthesis.…”

Section: Presentmentioning

confidence: 99%

Penile prosthesis implantation: past, present and future

Simmons

Montague

2008

Int J Impot Res

View full text Add to dashboard Cite

Penile prosthesis implantation is the oldest effective treatment for erectile dysfunction. This review examines the past, present and future of penile prosthesis implantation. Advances in prosthetic design and implantation techniques have resulted today in devices that produce nearly normal flaccid and erect states, and have remarkable freedom from mechanical failure. The future of prosthetic design holds promises for even more improvements.

show abstract

“…Pharmacotherapy is currently the mainstay treatment for ED. According to the suggestion of the American Urological Association (AUA) guideline on ED, the first-line treatment of ED should be phosphodiesterase type 5 (PDE5) inhibitors, which include sildenafil, tadalafil and vardenafil [3]. Treatment of ED with PDE5 inhibitors is generally well tolerated, although some side effects, such as headache, flushing, dyspepsia, nasal congestion and unusual visual disturbances, have been reported [4,5].…”

Section: Introductionmentioning

confidence: 99%

A 90-day Repeat-Dose Oral Toxicity Study of Yonkenafil Hydrochloride in Beagle Dogs

Liu¹,

Jin²,

Yu³

et al. 2017

J Biomedical Sci

View full text Add to dashboard Cite

Yonkenafil hydrochloride, a novel synthetic phosphodiesterase type 5 inhibitor, is a promising drug for the treatment of erectile dysfunction. The repeated-dose toxicity of yonkenafil hydrochloride was assessed in male and female beagle dogs. Twenty-four dogs were randomly allocated to four groups and administered yonkenafil hydrochloride orally at dosages of 0, 7, 30 or 120 mg/kg/day for 90 days followed by a 28-day recovery period. During the test period, clinical signs, mortality, body weight, food consumption, ophthalmoscopy, electrocardiography, hematology, serum biochemistry, urinalysis, organ weights, gross findings and histopathology were examined. There were no abnormal changes in the clinical observations except that gastrointestinal intolerance was observed in the 120 mg/kg/day group. The laboratory and histopathological examinations revealed yonkenafil hydrochloride toxicity to various organs, including the thyroid gland, liver, prostate, uterus and breast; at the end of the recovery period, this damage was resolved. The level of yonkenafil hydrochloride that resulted in no observable adverse effects in beagle dogs was 7 mg/kg/day.

show abstract

Chapter 1: The Management of Erectile Dysfunction: An Aua Update

Cited by 298 publications

References 47 publications

Vacuum therapy in erectile dysfunction—science and clinical evidence

Vacuum therapy in erectile dysfunction—science and clinical evidence

Penile prosthesis implantation: past, present and future

A 90-day Repeat-Dose Oral Toxicity Study of Yonkenafil Hydrochloride in Beagle Dogs

Contact Info

Product

Resources

About